The NASH PASS infrastructure and biobank are important and evolving platforms for translational research partnerships to advance scientific knowledge of NAFLD, NASH, and metabolic-related fibrotic disease pathology and progression, as well as the development of novel biomarkers for clinical research. Scientists and clinical development experts interested in biomarker discovery and validation, endpoint determination, and the study of NAFLD/NASH as a multi-system disorder can contact bd@prosciento.com for more information on collaborative research opportunities.
